Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
RegulatoryrejectedNegative
AI Analysis
Summary
The FDA has halted clinical testing of Regenxbio's Hunter syndrome gene therapy following detection of masses on the spines of five patients, marking the program's second clinical hold in 2026. This regulatory action raises significant safety concerns about the treatment candidate.
Clinical Trial Data
Primary Endpoint
Not Met
Patients
5
Outcome Details
FDA clinical hold on Hunter syndrome gene therapy due to detection of masses on spines of five patients; second clinical hold in 2026
Importance:9/10
Sentiment:
-0.95
clinical holdsafety concernsgene therapyFDA regulatory actionHunter syndrome
Related Companies
Read the original article
Published by BioPharma Dive on August 24, 2026 3:55 PM